



## Clinical and molecular genetic characterization of 5 patients with mutations in GNAS gene

Qun Li<sup>1</sup>, Guoying Chang<sup>1</sup>, Xin Li<sup>1</sup>, Yirou Wang<sup>1</sup>, Yufei Xu<sup>2</sup>, Guoqiang Li<sup>2</sup>, Juan Li<sup>1</sup>, Yu Ding<sup>1</sup>, Yao Chen<sup>1</sup>, jian Wang <sup>2\*</sup> and Xiumin Wang <sup>1\*</sup>

Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine

- Backgroud Inactivating mutations of the G NAS (gene encoding the alpha-subunit of Gs) g ene involving exon 1-13 which encode the alp ha-subunit of the stimulatory G protein (Gsa) are associated with several syndromes, including pseudohypoparathyroidism (PHP), pseudop seudohypoparathyroidism (PPHP) and progres sive osseous heteroplasia (POH).
- Method We collected clinical information of the patients, performed the targeted next g eneration sequencing and further verified wit h Sanger sequencing. The standards and guide lines from American College of Medical Geneti cs and Genomics was used to classify and interpret the pathogenicity for each genetic variant.





Result The diagnosis of PPHP was made in ca se 4. In case 5, POH was taken into consideration. All the five patients were found to carry the poss ibly causative variants, among which two variant s including a missense mutation (c.314C>T) and a splicing mutation (c.721+2 G>A) have never be en reported in patients before.

Table2. Clinical, laboratory, and imaging findings of five patients.

	Patient 1	Patient 2	Patient 3	Patient 4	Partient 5
Gender	Female	Female	Male	Male	Male
Birth					
Weeks	Term	Term	Term.	32w	36w
Birth weight (g)	2,900	2,800	3,500	1,610	2,000
Birth length (cm)	Unknown	50	Unknown	35	39
At diagnosis					
Age	2%ey	11*%cy	11% y	10 % y	10 m
Height (cm)	91	137.8	133	129.5	67
	(=0.5SD)	(-2.21 SD)	(-2.2SD)	(-2.085D)	(-2.76 SD)
Weight (kg) SDS	20	36.85	36.5	24.2	6.8
	(+4.9SD)	(-0.55 SD)	(~0.48SD)	(1.82SD)	(-2.82 SD)
BMI (kg/m²)	24.152	19.406	20.634	14.43	1
	(obese: ≥18.9)		(overweight: >20.1)		
AHO phenotype					
Short stature	No	Yes	Yes	Yes	Ne
Brachydactyly	No	Yes	Yes	Yes	No
Ectopic essifications	Yes	No	Yes	Yes	Progressive
Obesity	Yes	No	Yes	No	No
Round face	Yes	Yes	Yes	No	No
Intellectual disability	No	Ne	Yes	No	Ne
Hormone resistance					
PTH resistance	Yes	Yes	Yes	No	No
PTE	87 pg/mil	124.3 pg/ml	14.93 pmol/L	4.45 pmol/L	44.5 pg/ml
	(15:0-65:0) 7	(15.0-68.3) ↑	(1.6-6.9) †	(1.6-6.9)	(10.0-69.0)
Calcium (mmd/L)	2.70 (2.23-2.80)	2.32 (2.20-2.80)	1.25 (2.23-2.80)	2.44 (2.23-2.80)	2.37 (1.9-2.6)
Phosphorus (mmel/L)	2.19 (1.45-2.10) 1	1.66 (1.45-2.10)	>4.20 (1.45-2.10) 1	1.49 (1.45-2.10)	1.88 (1.2-1.9)
TSH resistance	Yes	Ne	Yes	No	1
TSH	5.72(0.34-5.60) ↑	4.706(0.35-4.94)	8.84(0.34-5.60) ↑	2.99(0.34-5.60)	1
FT4	11.71(7.86-19.20)	13.51(9.01-19.05)	7.25(7.86-19.20) [	12.88(7.86-19.20)	1
FT3	6.27(3.8-9.8)	3.78(2.63-5.70)	4.29(3.8-9.4)	6.44(3.8-9.4)	1
IGF-1 (ng/mL)	114.0	486	150	161.0	1
FSH/LH (mIU/mL)	11.54/0.58	1	6.74/2.23	3.60/2.67	1
ACTH (5.0-46.0 pg/mL)	29.5	/	12.1	21.2	1
25-OHD (>30.0 ng/mL)	16.97	Unknown	18.84	19.01	20.4
Other findings					
Brain MRI or CT	Normal	/	Calcification	Calcification	Normal

 Conclusion Our study expanded genotypic an d phenotypic spectrum of the GNAS related disorders.











